Vibrant Announces Positive Results of Pilot Trial Using Vibrating Capsule for Chronic Constipated Patients

Amsterdam, The Netherlands, October 18, 2012. Vibrant Ltd. today announced results of a pilot trial of the company's anti-constipation vibrating capsule. Fourteen (14) patients with chronic idiopathic constipation participated in and completed the study. Overall, there was a significant increase in the number of spontaneous bowel movements from 2.2 to 3.7 per week (p=0.0195). The results will be reported at the 20th United European Gastroenterology Week, to be held October 20-24, 2012 in Amsterdam, The Netherlands. The results will be presented on October 23, 2012 in Hall 1 (Poster No. P0964), from 9:00-17:00.

The mechanically operated capsule is a breakthrough treatment for constipated patients. It meets the highest safety standards and uses biocompatible materials.

The clinical trial was conducted at two Israeli hospitals. All patients underwent a two-week run-in period during which they were instructed to stop all laxatives. The capsule was activated and began vibrating a few hours after administration in a special mode developed by Vibrant. Each patient received two capsules per week and completed a daily bowel movement and laxative use questionnaire.

"This study showed for the first time that a swallowed capsule vibrating in the colon is safe, and it affects spontaneous bowel movements for constipated patients and improves their symptoms," said Lior Ben-Tsur, Vibrant Chief Executive Officer. ”We are very encouraged by the results and we will continue exploring this novel concept."

Vibrant is currently raising funds from private investors to complete a financing round that will enable the company to complete a multi-center clinical study and prepare for market launch.

Vibrant constipation relief technology is based on the effect of the capsule’s vibrations on the wall of the large intestine, consequently inducing peristaltic activity and generating spontaneous additional bowel movement. The easy-to-swallow capsule is controlled through algorithms, predefined by Vibrant R&D and gastroenterology advisers.

The capsule is activated by a base unit that transfers the predefined algorithm's data into the capsule, before it is swallowed. The capsule operates inside the large intestine and is flushed out of the body with the bowel movement, leaving no chemicals in the body.

The company plans to complete the pivotal clinical trial by Q3 of 2013 and obtain CE mark.

About Vibrant

Founded in 2007 in Israel, Vibrant is a medical device company. Its major breakthrough is a technological platform for various constipated groups of patients. This innovative platform relies on known physiological parameters of large intestinal peristaltic movement. The first product based on the company's technology is a proprietary, biocompatible, chemical-free capsule providing effective aid for chronic constipation patients. Vibrant is owned by the founders and private investors. For more information, visit www.vibrantgastro.com.

Contact:

Lior Ben-Tsur

Vibrant Ltd.

Tel.: +972-54-6950001

e-mail: lior.b@vibrantgastro.com

MORE ON THIS TOPIC